Table 1.

Retrospective series that evaluated patients with CNSm from EOC.

Author, year (reference)	Regimen of chemotherapy*	Number of patients with CNSm	Median interval between diagnosis of EOC and CNSm in months (range)	Median survival after diagnosis of OC in months (range)	Median survival after diagnosis of CNS metastases in months (range)
Anupol et al., 2002 [6]	Cisplatin and paclitaxel	15	22 (0–53)	38 (9–82)	6 (0–49)
Cohen et al., 2004 [7]	Cisplatin and paclitaxel	72	22 (0–219)	40.5 (21.5–60)	6.3 (5–8)
Chen et al., 2011 [8]	Carboplatin and paclitaxel	10	24.3 (7–55)	NA	3 (0–16)
Kumar et al., 2003 [9]	Carboplatin and paclitaxel	18	29 (0–101)	30.5 (5–110)	4 (1–74)
Tay and Ajesh, 2005 [10]	Carboplatin and paclitaxel	4	16.5 (8–65)	NA	19,5
Kastritis et al., 2006 [11]	Carboplatin and paclitaxel	8	17,2	67 (48–85)	22 (12–34)

^*Adjuvant, palliative, or neoadjuvant chemotherapy received before diagnosis of CNSm.